Healthcare

Dassault Systèmes unifies life-sciences and healthcare AI platform

Dassault Systèmes completed its acquisition of ArisGlobal and announced a unified AI platform spanning drug discovery, clinical development and patient outcomes.

Dassault Systèmes announced the completion of its acquisition of ArisGlobal and the combination of its life-sciences and healthcare capabilities into a unified AI platform. The company said the platform connects scientific discovery, clinical development, manufacturing and patient outcomes.

The platform is being developed within Dassault Systèmes’ 3D UNIV+RSES environment. It is designed to bring together data and workflows across the drug lifecycle rather than treating research, development and patient information as separate activities.

The company described the system as AI-native and said it combines artificial intelligence with scientific expertise and virtual-twin technologies. The intended result is a continuous cycle of discovery, learning and improvement.

The deal matters because it reflects consolidation in healthcare and life-sciences software. Vendors are increasingly combining AI, simulation, clinical-development tools and real-world patient data to support pharmaceutical and medical-product development.

Original source: GlobeNewswire

Related RAQI solutions

In-depth analysis on RAQI Insight

Work with RAQI